Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution platform is based on the Genio® system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.
2009
Served areaWorldwide
HeadquartersRue Edouard Belin 12, 1435 Mont-Saint-Guibert – Belgium
25,846,279
IPOSept. 18, 2020
Stock exchange(s)Euronext Brussels